Olorinab

Olorinab
Olorinab structure.png
Clinical data
Routes of
administration
Oral
Identifiers
CAS Number
PubChem CID
Chemical and physical data
Formula C18H24N5O3
Molar mass 358.414 g/mol g·mol−1
3D model (JSmol)

Olorinab (APD371) is a drug developed by Arena Pharmaceuticals for the treatment of pain associated with Crohn’s disease. It acts as a potent and selective cannabinoid CB2 receptor agonist and is claimed to be orally active and peripherally selective, and has progressed to Phase II clinical trials.[1][2]

See also[edit]

References[edit]

  1. ^ Han S, Thoresen L, Jung JK, Zhu X, Thatte J, Solomon M, et al. (December 2017). “Discovery of APD371: Identification of a Highly Potent and Selective CB2 Agonist for the Treatment of Chronic Pain”. ACS Medicinal Chemistry Letters. 8 (12): 1309–1313. doi:10.1021/acsmedchemlett.7b00396. PMID 29259753.
  2. ^ “Olorinab (APD371)”. Arena Pharmaceuticals, Inc.